{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T06:41:15Z","timestamp":1792046475551,"version":"4.4.0"},"reference-count":54,"publisher":"Consilium Medicum","issue":"8","license":[{"start":{"date-parts":[[2019,8,15]],"date-time":"2019-08-15T00:00:00Z","timestamp":1565827200000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-sa\/4.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Terapevticheskii arkhiv"],"abstract":"<jats:p>From the standpoint of evidence - based medicine, the ability of various drugs to induce the development of gastroesophageal reflux disease and esophagitis is considered. Thus, all known drugs can be divided into 3 groups: drugs that have the ability to reduce pressure in the lower esophageal sphincter, for example, \u03b2-adrenoreceptor agonists, \u03b1-adrenoreceptor antagonists, anticholinergics, calcium channel blockers, nitrates, benzodiazepines (diazepam), estrogen, progesterone, aminophylline (theophylline), tricyclic antidepressants, selective serotonin reuptake inhibitors, glucocorticosteroids; means providing a direct damaging effect on the esophageal mucosa, as well as lowering its resistance reflyuktatu, e.g., bisphosphonates, acetylsalicylic acid \/ non - steroidal anti - inflammatory agents, anticoagulants, antiplatelet drugs, iron preparations, ascorbic acid, potassium chloride, quinidine, phenytoin, calcium dobesilate, 131I sodium iodide, antibiotics (tetracycline, doxycycline, clindamycin, ciprofloxacin, ornidazole, clindamycin, rifampicin), antitumor agents; drugs that impede gastric emptying: calcium channel blockers, anticholinergics. These data can be used in practice in the choice of treatment tactics, especially in individuals with a diagnosis of gastroesophageal reflux disease or heartburn.<\/jats:p>","DOI":"10.26442\/00403660.2019.08.000228","type":"journal-article","created":{"date-parts":[[2019,9,7]],"date-time":"2019-09-07T21:59:22Z","timestamp":1567893562000},"page":"135-140","source":"Crossref","is-referenced-by-count":9,"title":["Gastroesophageal reflux disease and esophagitis associated with the use of drugs: the modern state of the problem"],"prefix":"10.26442","volume":"91","author":[{"given":"A M","family":"Osadchuk","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I L","family":"Davydkin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T A","family":"Gricenko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M A","family":"Osadchuk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"18344","published-online":{"date-parts":[[2019,8,15]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2012-304269"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1442-2050.2009.00972.x"},{"key":"ref3","unstructured":"\u041f\u0430\u0445\u043e\u043c\u043e\u0432\u0430 \u0418.\u0413., \u0425\u043e\u0440\u043e\u0448\u0438\u043d\u0438\u043d\u0430 \u041b.\u041f. \u041d\u041f\u0412\u041f-\u0438\u043d\u0434\u0443\u0446\u0438\u0440\u043e\u0432\u0430\u043d\u043d\u0430\u044f \u044d\u0437\u043e\u0444\u0430\u0433\u043e\u043f\u0430\u0442\u0438\u044f: \u043f\u0440\u043e\u0441\u0442\u043e \u0413\u042d\u0420\u0411 \u0438\u043b\u0438 \u0435\u0449\u0435 \u043e\u0434\u043d\u0430 \u043d\u043e\u0437\u043e\u043b\u043e\u0433\u0438\u0447\u0435\u0441\u043a\u0430\u044f \u0435\u0434\u0438\u043d\u0438\u0446\u0430? \u0424\u0430\u0440\u043c\u0430\u0442\u0435\u043a\u0430. 2016;15(328):39-43."},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1111\/j.1442-2050.2011.01287.x"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2036.2008.03708.x"},{"key":"ref6","doi-asserted-by":"crossref","unstructured":"Kotzan J, Wade W, Yu H.H. Assessing NSAID prescription use as a predisposing factor for gastroesophageal reflux disease in a Medicaid population. Pharm Res. 2001;18:1367-72.","DOI":"10.1023\/A:1013010616496"},{"key":"ref7","doi-asserted-by":"crossref","unstructured":"Ruig\u00f3mez A, Garc\u00eda Rodr\u00edguez L.A, Wallander M.A, Johansson S, Graffner H, Dent J. Natural history of gastro - oesophageal reflux disease diagnosed in general practice. Aliment Pharmacol Ther. 2004;20:751-60.","DOI":"10.1111\/j.1365-2036.2004.02169.x"},{"key":"ref8","unstructured":"Scheiman J.M, Patel P.M, Henson E.K, Nostrant T.T. Effect of naproxen on gastroesophageal reflux and esophageal function: a randomized, double - blind, placebo - controlled study. Am J Gastroenterol. 1995;90:754-7."},{"key":"ref9","unstructured":"Duh M.S, Gosselin A, Luo R, Lohoues H, Lewis B.E, Crawley J.A. Impact of compliance with proton pump inhibitors on NSAID treatment. Am J Manag Care. 2009;15:681-8."},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2036.2008.03821.x"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1586\/egh.12.61"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1007\/s00535-018-1483-x"},{"key":"ref13","doi-asserted-by":"crossref","unstructured":"Harirforoosh S, Asghar W, Jamali F. Adverse effects of nonsteroidal antiinflammatory drugs: an update of gastrointestinal, cardiovascular and renal complications. J Pharm Pharm Sci. 2013;16(5):821-47.","DOI":"10.18433\/J3VW2F"},{"key":"ref14","doi-asserted-by":"crossref","unstructured":"Taha A.S, Mc Closkey C, Prasad R, Bezlyak V. Famotidine for the prevention of peptic ulcers and oesophagitis in patients taking lowdose aspirin (FAMOUS): a phase III, randomised, double - blind, placebo - controlled trial. Lancet. 2009;374:119-25.","DOI":"10.1016\/S0140-6736(09)61246-0"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2016-313589"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2008.03.039"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1186\/1471-230X-12-56"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2008.01.009"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.168.16.1798"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.9734\/BJMMR\/2017\/31790"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v22.i3.906"},{"key":"ref22","unstructured":"Ettinger B, Pressman A, Schein J. Clinic visits and hospital admissions for care of acid - related upper gastrointestinal disorders in women using alendronate for osteoporosis. Am J Manag Care. 1998;4:1377-82."},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1038\/ajg.2013.222"},{"key":"ref24","doi-asserted-by":"crossref","unstructured":"Miyamoto M, Haruma K, Kuwabara M, Nagano M, Okamoto T, Tanaka M. High incidence of newly - developed gastroesophageal reflux disease in the Japanese community: a 6-year follow - up study. J Gastroenterol Hepatol. 2008 Mar;23(3):393-7.","DOI":"10.1111\/j.1440-1746.2007.05043.x"},{"key":"ref25","doi-asserted-by":"crossref","unstructured":"Nakaji G, Fujihara M, Fukata M, Yasuda S, Odashiro K, Maruyama T, Akashi K. Influence of common cardiac drugs on gastroesophageal reflux disease: multicenter questionnaire survey. Int J Clin Pharmacol Ther. 2011;49:555-62.","DOI":"10.5414\/CP201558"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.2007.02851.x"},{"key":"ref27","doi-asserted-by":"crossref","unstructured":"Stacher G, Schneider C, Steinringer H, Holz\u00e4pfel A, Gaupmann G, Stacher-Janotta G. Effects of 3-days' intake of a sustained - release preparation of the nitric oxide donor, isosorbide dinitrate, on oesophageal motility. Aliment Pharmacol Ther. 1997 Oct;11(5):967-71.","DOI":"10.1046\/j.1365-2036.1997.00241.x"},{"key":"ref28","unstructured":"Nasseri-Moghaddam S, Mofid A, Razjouyan H. Dietary nitrate may have a role in development of gastro - esophageal reflux disease. Arch Iran Med. 2011 Sep; 14(5):312-4."},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.1080\/14656566.2017.1361407"},{"key":"ref30","doi-asserted-by":"crossref","unstructured":"Mart\u00edn-Merino E, Ruig\u00f3mez A, Garc\u00eda Rodr\u00edguez L.A, Wallander M.A, Johansson S. Depression and treatment with antidepressants are associated with the development of gastro - oesophageal reflux disease. Aliment Pharmacol Ther. 2010;31:1132-40.","DOI":"10.1111\/j.1365-2036.2010.04280.x"},{"key":"ref31","doi-asserted-by":"crossref","unstructured":"Van Soest E.M, Dieleman J.P, Siersema P.D, Schoof L, Sturkenboom M.C, Kuipers E.J. Tricyclic antidepressants and the risk of reflux esophagitis. Am J Gastroenterol. 2007;102:1870-7.","DOI":"10.1111\/j.1572-0241.2007.01320.x"},{"key":"ref32","unstructured":"Rushnak M.J, Leevy C.M. Effect of diazepam on the lower esophageal sphincter. A double - blind controlled study. Am J Gastroenterol. 1980;73:127-32."},{"key":"ref33","unstructured":"Singh S, Bailey R.T, Stein H.J, De Meester T.R, Richter J.E. Effect of alprazolam (Xanax) on esophageal motility and acid reflux. Am J Gastroenterol. 1992;87:483-8."},{"key":"ref34","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2009.04.026"},{"key":"ref35","doi-asserted-by":"crossref","unstructured":"Koerselman J, Pursnani K.G, Peghini P, Mohiuddin M.A, Katzka D, Akkermans L.M, Castell D.O. Different effects of an oral anticholinergic drug on gastroesophageal reflux in upright and supine position in normal, ambulant subjects: a pilot study. Am J Gastroenterol. 1999;94:925-30.","DOI":"10.1111\/j.1572-0241.1999.988_k.x"},{"key":"ref36","doi-asserted-by":"crossref","unstructured":"Ciccaglione A.F, Grossi L, Cappello G, Malatesta M.G, Ferri A, Toracchio S, Marzio L. Effect of hyoscine Nbutylbromide on gastroesophageal reflux in normal subjects and patients with gastroesophageal reflux disease. Am J Gastroenterol. 2001;96:2306-11.","DOI":"10.1111\/j.1572-0241.2001.04034.x"},{"key":"ref37","doi-asserted-by":"publisher","DOI":"10.4103\/sjg.SJG_518_17"},{"key":"ref38","doi-asserted-by":"publisher","DOI":"10.1111\/all.13342"},{"key":"ref39","doi-asserted-by":"publisher","DOI":"10.5152\/tjg.2017.11"},{"key":"ref40","doi-asserted-by":"crossref","unstructured":"Crowell M.D, Zayat E.N, Lacy B.E, Schettler-Duncan A, Liu M.C. The effects of an inhaled beta(2)-adrenergic agonist on lower esophageal function: a dose - response study. Chest. 2001;120(4):1184-9.","DOI":"10.1378\/chest.120.4.1184"},{"key":"ref41","doi-asserted-by":"publisher","DOI":"10.3904\/kjim.2014.29.4.466"},{"key":"ref42","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v23.i17.3011"},{"key":"ref43","doi-asserted-by":"publisher","DOI":"10.1089\/jpm.2009.0404"},{"key":"ref44","doi-asserted-by":"crossref","unstructured":"Dahms B.B, Greco M.A, Strandjord S.E, Rothstein F.C. Barrett's esophagus in three children after antileukemia chemotherapy. Cancer. 1987 Dec 15;60(12):2896-900.","DOI":"10.1002\/1097-0142(19871215)60:12<2896::AID-CNCR2820601208>3.0.CO;2-P"},{"key":"ref45","doi-asserted-by":"crossref","unstructured":"Peters F.T, Sleijfer D.T, van Imhoff G.W, Kleibeuker J.H. Is chemotherapy associated with development of Barrett's esophagus? Dig Dis Sci. 1993 May;38(5):923-6.","DOI":"10.1007\/BF01295921"},{"key":"ref46","doi-asserted-by":"publisher","DOI":"10.1097\/MPH.0b013e318217237b"},{"key":"ref47","doi-asserted-by":"publisher","DOI":"10.1097\/MPH.0b013e3181ccb678"},{"key":"ref48","doi-asserted-by":"crossref","unstructured":"Biacabe B, Gleich L.L, Laccourreye O, Hartl D.M, Bouchoucha M, Brasnu D. Silent gastroesophageal reflux disease in patients with pharyngolaryngeal cancer: further results. Head Neck. 1998 Sep;20(6):510-4.","DOI":"10.1002\/(SICI)1097-0347(199809)20:6<510::AID-HED4>3.0.CO;2-0"},{"key":"ref49","unstructured":"Asai S, Nagai K, Takahashi N, Watanabe T, Matsumoto T, Asai N, Sobue Y, Ishiguro N, Kojima T. Influence of methotrexate on gastrointestinal symptoms in patients with rheumatoid arthritis. Int J Rheum Dis. 2018 Aug 30. doi: 10\/1111\/1756-185\u0425.13380"},{"key":"ref50","unstructured":"\u0414\u0430\u0432\u044b\u0434\u043a\u0438\u043d \u0418.\u041b., \u041e\u0441\u0430\u0434\u0447\u0443\u043a \u0410.\u041c., \u0413\u0440\u0438\u0446\u0435\u043d\u043a\u043e \u0422.\u0410., \u041a\u0443\u0440\u0442\u043e\u0432 \u0418.\u0412. \u0420\u0435\u0444\u0440\u0430\u043a\u0442\u0435\u0440\u043d\u0430\u044f \u0444\u043e\u0440\u043c\u0430 \u0433\u0430\u0441\u0442\u0440\u043e\u044d\u0437\u043e\u0444\u0430\u0433\u0435\u0430\u043b\u044c\u043d\u043e\u0439 \u0440\u0435\u0444\u043b\u044e\u043a\u0441\u043d\u043e\u0439 \u0431\u043e\u043b\u0435\u0437\u043d\u0438: \u044d\u0432\u043e\u043b\u044e\u0446\u0438\u044f \u043f\u0440\u0435\u0434\u0441\u0442\u0430\u0432\u043b\u0435\u043d\u0438\u0439. \u041d\u0430\u0443\u043a\u0430 \u0438 \u0438\u043d\u043d\u043e\u0432\u0430\u0446\u0438\u0438 \u0432 \u043c\u0435\u0434\u0438\u0446\u0438\u043d\u0435. 2017;1(5):24-30."},{"key":"ref51","doi-asserted-by":"publisher","DOI":"10.3164\/jcbn.12-83"},{"key":"ref52","doi-asserted-by":"crossref","unstructured":"Lazenby J.P, Guzzo M.R, Harding S.M, Patterson P.E, Johnson L.F, Bradley L.A. Oral corticosteroids increase esophageal acid contact times in patients with stable asthma. Chest. 2002 Feb;121(2):625-34.","DOI":"10.1378\/chest.121.2.625"},{"key":"ref53","doi-asserted-by":"crossref","unstructured":"S\u00f8rensen H.T, Mellemkjaer L, Friis S, Olsen J.H. Use of Systemic Corticosteroids and Risk of Esophageal Cancer. Epidemiology. 2002 Mar;13(2):240-1.","DOI":"10.1097\/00001648-200203000-00027"},{"key":"ref54","doi-asserted-by":"publisher","DOI":"10.1097\/01.anes.0000365963.97138.54"}],"container-title":["Terapevticheskii arkhiv"],"original-title":[],"link":[{"URL":"https:\/\/ter-arkhiv.ru\/0040-3660\/article\/viewFile\/33675\/pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/ter-arkhiv.ru\/0040-3660\/article\/viewFile\/33675\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,10,13]],"date-time":"2021-10-13T21:36:55Z","timestamp":1634161015000},"score":1,"resource":{"primary":{"URL":"https:\/\/ter-arkhiv.ru\/0040-3660\/article\/view\/33675"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,8,15]]},"references-count":54,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2019,8,15]]}},"URL":"https:\/\/doi.org\/10.26442\/00403660.2019.08.000228","relation":{},"ISSN":["2309-5342","0040-3660"],"issn-type":[{"value":"2309-5342","type":"electronic"},{"value":"0040-3660","type":"print"}],"subject":[],"published":{"date-parts":[[2019,8,15]]}}}